State Peptide Regulation Fills the Federal Oversight Gap

Federal rules for compounded GLP-1 drugs are now settled, but the legal status of most compounded peptides remains an open question — and state boards, attorneys general, and legislatures are increasingly filling the gap with their own oversight. A Sheppard Mullin analysis published Aug. 6, 2026 maps how states are regulating above the federal floor, and why the resulting patchwork matters for prescribers and patients.

The Federal Baseline Is Settled — for GLP-1s

The compounding baseline is fixed federally, chiefly by Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. States cannot fall below that floor; they can only add stricter conditions on top of it. For GLP-1 receptor agonists, the federal picture has largely resolved. The molecules were never on the 503A or 503B Bulks Lists, and their compounding was permitted only through the drug shortage pathway, which closed as the FDA resolved the tirzepatide and semaglutide shortages.

The agency reinforced the point through its “essentially a copy” guidance under 503A(b)(2), a proposal to exclude the molecules from the 503B Bulks List, and successive waves of dozens of warning letters. The net effect, as the Sheppard Mullin authors put it, is that “the substantive federal rules for GLP-1 copies are now reasonably settled and restrictive.” We covered the enforcement trajectory in FDA compounding pharmacy enforcement intensifies ahead of July PCAC.

The Peptide Gray Zone

Peptides occupy a very different position. In 2023, the FDA placed popular peptides in Category 2 of the interim 503A bulk scheme, effectively barring their compounding on safety grounds. In April 2026, the FDA removed twelve of those peptides from Category 2 and scheduled Pharmacy Compounding Advisory Committee (PCAC) meetings to consider adding them to Category 1 — the 503A Bulks List.

Removal from Category 2 is not authorization. The twelve peptides now sit in a regulatory gray zone: no longer explicitly flagged as presenting a significant safety risk, but not affirmatively cleared for compounding either. That distinction is central to the state story, because a federal loosening would ripple outward: if the FDA ultimately places the peptides on the 503A Bulks List, the federal-default states “will effectively loosen with it, without any state action required.” Until PCAC rules, state-level peptide regulation is the main source of legal clarity — and it is uneven.

How States Are Responding

Only one state has enacted a codified, stricter standard for compounded GLP-1s and peptides: California, whose rule took effect Oct. 1, 2025 and requires a documented “clinically significant, patient-specific difference” plus a certificate of analysis naming the manufacturer. Everywhere else, the response is guidance, enforcement posture, or silence.

California: The Codified Outlier

California’s rule has the force of law, making it the outlier among the states surveyed. Compounding of GLP-1 copies and peptides there must clear a patient-specific clinical justification and a paper trail back to the named manufacturer.

Ohio and Washington: Enforcement First

Ohio’s July 2025 guidance bans copy compounding after the shortages closed, expressly prohibits the investigational peptides retatrutide and cagrilintide, and requires Ohio-licensed distributors. The state board reports summarily suspending more than thirty clinics and medical spas since the beginning of 2025. Washington imposed a stop-service order on a GLP-1 sterile compounder over sterile compounding and licensure failures. Both states signal that board enforcement, not rulemaking, is the primary tool.

Alabama and New Jersey: Ingredient Guidance

Alabama and New Jersey have issued statements prohibiting salt forms and requiring pharmaceutical-grade active ingredients sourced from an FDA-registered manufacturer with a valid certificate of analysis. Similar board statements have come from West Virginia, Oregon, Kansas, and Kentucky — guidance that constrains what compounders may use even where no specific peptide rule exists.

Connecticut: Consumer Protection Levers

Connecticut’s attorney general has pursued enforcement under the state’s unfair trade practices statute, and Illinois and South Carolina have issued similar consumer alerts. This is a different regulatory lane: rather than regulating compounders directly, these states police the marketing and sale of compounded GLP-1s and peptides as consumer protection matters.

Texas and Florida: The Silent Majority

Texas and Florida have no GLP-1-specific board position. Both operate under general frameworks that incorporate the federal “essentially a copy” standard and USP compounding chapters, with Florida’s sterile rule tied to FD&C Section 503A. For prescribers and patients in these states, the practical answer is closer to the federal floor — until something changes.

What This Means for Peptide Prescribers

The practical takeaway is that peptide regulation now varies meaningfully by state, and the variance can change a prescriber’s obligations overnight:

• Know your board’s posture. California requires a documented patient-specific clinical difference; Ohio bans copy compounding post-shortage; Alabama and New Jersey set the active-ingredient standard. Prescribers relying on a compounding pharmacy should confirm which standard their state applies.
• Guidance is not static. Most state actions are guidance or enforcement posture, not codified law, which means they can shift with new board leadership or new FDA action. The one codified rule — California’s — is the exception, not the template.
• Watch the federal clock. If PCAC recommends Category 1 placement for some of the twelve peptides, federal-default states may loosen automatically with no state action. Prescribers should treat the PCAC docket as the single biggest swing factor in the state-by-state landscape.

What This Means for Patients

For patients, the state patchwork means the same compounded peptide can have a very different legal and quality-assurance backdrop depending on where it is dispensed. States that require pharmaceutical-grade ingredients from FDA-registered sources and certificates of analysis — California, Alabama, New Jersey, and their peers — create a stronger paper trail for what is actually in the vial. States without specific positions leave patients closer to the federal baseline, where the gray zone is widest.

A few practical cautions: absence of a state rule does not mean the FDA has cleared a product, and “removed from Category 2” is not the same as “approved for compounding.” Patients should confirm that any compounded peptide they are prescribed comes from a licensed pharmacy operating under a documented standard, and should be wary of marketing that implies FDA approval for products that have never been cleared. Brand manufacturers are also active here — Eli Lilly and Novo Nordisk have filed trademark, patent, and false advertising suits across dozens of jurisdictions, and at least one compounder has countersued on antitrust grounds.

What to Watch Next

The next decision point is the PCAC process on Category 1 placement for the twelve peptides removed from Category 2 in April. A favorable recommendation would loosen the federal-default states without further action; an unfavorable one would keep the gray zone in place. Either way, the states that have already acted — California’s codified rule, Ohio and Washington’s enforcement, Connecticut’s consumer protection — have established the playbook others are likely to follow.

State peptide regulation is not a sideshow to the federal story; it is, for now, the main event. Tracking both the PCAC calendar and the state boards that move faster than Washington is the way to stay ahead of the patchwork. See our state-by-state peptide regulation tracker and the July PCAC preview for the details.

PeptidesBeat is an independent editorial publication covering peptide policy, research, and industry developments. We do not sell peptides, recommend dosing, or provide medical advice. All content is informational. Peptides referenced may be subject to FDA restrictions; consult a licensed healthcare provider for any therapeutic question.